Pazopanib: Approval for Soft-Tissue Sarcoma
Diana T. Nguyen, PharmD, and Sepideh Shayahi, PharmD, BCOP
From City of Hope Medical Center, Duarte, California
The authors have no conflicts of interest to disclose.
Correspondence to: Diana T. Nguyen, PharmD, City of Hope Medical Center, Helford Hospital, 1500 East Duarte Road, Duarte, CA 91010. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2012;4:53–57 |
DOI: 10.6004/jadpro.2013.4.1.6 |
© 2013 Harborside Press®
Pazopanib (Votrient), an oral, multitargeted tyrosine kinase inhibitor that was previously approved by the FDA for advanced renal cell carcinoma, recently gained FDA approval for select patients with soft-tissue sarcoma as well. Learn more about this agent, including the studies that led to its approval, its adverse event profile, and other implications for the AP in oncology.
For access to the full length article, please sign in